Results 151 to 160 of about 1,815 (184)

The comparative efficacy of SGLT-2 inhibitors and GLP-1 receptor agonists on metabolic benefits in T2DM patients: a systematic review and network meta-analysis. [PDF]

Eur J Med Res
Tong J, Li N, Hu F, Yue Y.
europepmc   +1 more source

The Impact of Sodium Glucose Co-Transporter 2 (SGLT-2) Inhibitors on Atherogenesis: A Systematic Review of Experimental and Clinical Evidence. [PDF]

Life (Basel)
Gurgoglione FL, Covani M, Torlai Triglia L, Benatti G, Donelli D, Bianconcini M, Solinas E, Tadonio I, Denegri A, De Gregorio M, Dallaglio G, Dei Cas A, Bonadonna RC, Vignali L, Niccoli G.   +14 more
europepmc   +1 more source

Effect of Tofogliflozin on Cardiac Function: Potential Link Between Ketone Bodies and the Heart

Journal of Endocrinology and Metabolism, 2017
openaire   +2 more sources

Effects of Sodium Glucose Co-Transporter 2 Inhibitors on Atrial Fibrillation Recurrences After Catheter Ablation in Atrial Fibrillation Patients: A Systematic Review and Meta-Analysis. [PDF]

J Clin Med
Parsi S, Sonavane K, Ravi U, Shirsat PD, Chamarthi VS, Gabr M, Ponnam HC, Surani S, Bansal V, Kashyap R.   +9 more
europepmc   +1 more source

Increasing Prescription of SGLT2 Inhibitors with Expanded Indications to the Elderly Population in Japan. [PDF]

Kidney Dis (Basel)
Oda Y, Nishi H, Sekiguchi M, Odawara M, Nangaku M.   +4 more
europepmc   +1 more source

Impact of Sodium-Glucose Cotransporter-2 Inhibitors on Post-Transurethral Resection of Bladder Tumor Infection and Prognosis. [PDF]

Diagnostics (Basel)
Nishimura N, Miyake M, Miyamoto T, Ichii D, Naoi M, Narita K, Kohashi M, Tomioka A, Torimoto K, Kawashima R, Miyazaki K, Iwao T, Inoue K, Matsubara T, Fujimoto K.   +14 more
europepmc   +1 more source

Metabolic adaptation to acute metabolic stress via PFKFB3 upregulation in rodent beta cells. [PDF]

Front Endocrinol (Lausanne)
Chiba K, Nomoto H, Izumihara R, Zhang X, Kameda H, Nakamura A, Atsumi T.   +6 more
europepmc   +1 more source

Pharmacological profile of tofogliflozin, a novel SGLT2 inhibitor, in preclinical studies

Pharmacological profile of tofogliflozin, a novel SGLT2 inhibitor, in preclinical studies
openaire  

Some of the next articles are maybe not open access.

Related searches:

Impact of tofogliflozin on hepatic outcomes: a systematic review

European Journal of Clinical Pharmacology, 2023
Studies have demonstrated a high prevalence of non-alcoholic fatty liver disease (NAFLD) in type 2 diabetes mellitus (T2DM) patients. The aim was to review the effect of tofogliflozin on hepatic outcomes in T2DM patients.A literature search in PubMed, Science Direct and Cochrane Central Register of Controlled Trials was conducted for randomised ...
Mani, Pathak, Rizwana, Parveen, Parvej, Khan, Nilanjan, Saha, Nidhi, Agarwal   +4 more
openaire   +2 more sources